SCHEMBL567416

SCHEMBL567416

CC(=O)c1ccc(OCc2ccccc2)cc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MAOB P27338 16/20 1.00
MAOA P21397 8/20 0.74
MAPT P10636 1/20 0.67
HTT P42858 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
PPARD Q03181 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29945833 1.00 MAOB (1.00) MAOBMAOAMAPTHTTL3MBTL1
SCHEMBL560607 0.89 MAOB (0.81) MAOBMAOAMAPTHTTL3MBTL1
SCHEMBL29369517 0.88 MAOB (0.78) MAOBMAOAMAPTL3MBTL1
SCHEMBL384341 0.88 MAOB (0.78) MAOBMAOAMAPTL3MBTL1
SCHEMBL7550950 0.87 MAOB (0.77) MAOBMAOAPPARD
SCHEMBL1519064 0.87 MAOB (0.77) MAOBMAOA
SCHEMBL7796801 0.87 MAOB (0.77) MAOBMAOA
SCHEMBL31166914 0.86 MAOB (0.76) MAOBMAOAMAPTHTTL3MBTL1
SCHEMBL588979 0.86 MAOB (0.76) MAOBMAOAMAPTHTTL3MBTL1
SCHEMBL3540404 0.86 MAOB (0.76) MAOBMAOAMAPTHTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024104139-A1 COMPOSITE MATERIAL, LIGHT-EMITTING DEVICE COMPRISING SAME, AND PREPARATION METHOD THEREFOR TCL科技集团股份有限公司 2024-05-23 WO claimed
CN-114146071-B Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome 西北农林科技大学深圳研究院 2023-02-28 CN claimed
CN-114146071-A Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome 西北农林科技大学深圳研究院 2022-03-08 CN claimed
CN-107827849-B 6- [ 2-hydroxy-3- (alkylamino) propoxy ] benzofuran compound and application thereof 沈阳药科大学 2020-06-02 CN claimed
EP-1566175-B1 Topical preparation comprising at least one aryloxime and bisabolol MERCK PATENT GMBH (DE) 2006-10-25 EP claimed
US-20250270220-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-08-28 US disclosed
US-12304915-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2025-05-20 US disclosed
EP-4549424-A1 NEW LITHIUM EXTRACTING AGENT AND LIQUID ORGANIC MIXTURE THEREOF, AND METHOD FOR EXTRACTING LITHIUM BY MEANS OF EXTRACTION Beijing Salt Lake Technology Development Company Limited (CN) 2025-05-07 EP disclosed
WO-2025078542-A1 COUMARIN-METAL COMPLEXES AND USES THEREOF TECHNOLOGICAL UNIVERSITY DUBLIN (IE) 2025-04-17 WO disclosed
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 US disclosed
US-20240254135-A1 POLYPHENOL COMPOUNDS EPIRIUM BIO INC (US) 2024-08-01 US disclosed
WO-2024104139-A1 COMPOSITE MATERIAL, LIGHT-EMITTING DEVICE COMPRISING SAME, AND PREPARATION METHOD THEREFOR TCL科技集团股份有限公司 2024-05-23 WO disclosed
US-4290957-A SWEETENERS DYNAPOL (US) 1981-09-22 US disclosed
US-4285965-A FUNGICIDES AND INSECTICIDES FOR PLANTS BAYER AKTIENGESELLSCHAFT (DE) 1981-08-25 US disclosed
US-4283434-A FOR FOODS NUTRASWEET COMPANY THE 1981-08-11 US disclosed
US-4267165-A Comestibles sweetened with alpha amino acid dihydrochalcones DYNAPOL (US) 1981-05-12 US disclosed
EP-0000377-B1 PROCESS FOR THE PREPARATION OF CHROMONE DERIVATIVES, NEW CHROMONE DERIVATIVES AND THEIR USE AS PLANT-PROTECTING AGENTS BAYER AG (DE) 1981-01-21 EP disclosed
US-4226804-A ARTIFICIAL SWEETENER DYNAPOL (US) 1980-10-07 US disclosed
US-4204007-A 4-(Dihydroxyhexoxy)dihydrochalcone sweeteners DYNAPOL (US) 1980-05-20 US disclosed
US-4189498-A FUNGICIDES, ARTHROPODICIDES BAYER AKTIENGESELLSCHAFT (DE) 1980-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162863-B2 Modulators of stimulator of interferon genes (STING) STING1, IRF3, CGAS MAOB 730/4885MAOA 747/4885MAPT 1787/4885
US-12304915-B2 SOS1 inhibitors SOS1, SOS2, SAV1 MAOB 3798/4885MAOA 4187/4885MAPT 3786/4885
US-20250270220-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 MAOB 3798/4885MAOA 4187/4885MAPT 3786/4885
US-20240254135-A1 POLYPHENOL COMPOUNDS COMT, MAPT, PPARG MAOB 1155/4885MAOA 1442/4885MAPT 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.